NERLYNX Drug Patent Profile

Which patents cover Nerlynx, and what generic alternatives are available?

Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixteen patent family members in thirty-six countries.

The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.

DrugPatentWatch^® Generic Entry Outlook for Nerlynx

Nerlynx was eligible for patent challenges on July 17, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 29, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (neratinib maleate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NERLYNX

International Patents:	216
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NERLYNX

Paragraph IV (Patent) Challenges for NERLYNX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NERLYNX	Tablets	neratinib maleate	40 mg	208051	1	2021-07-19

US Patents and Regulatory Information for NERLYNX

NERLYNX is protected by twenty US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y	Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes			Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes

International Patents for NERLYNX

See the table below for patents covering NERLYNX around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2011010511	REGIMEN DE TRATAMIENTO QUE UTILIZA NERATINIB PARA CANCER DE MAMA. (TREATMENT REGIMEN UTILIZING NERATINIB FOR BREAST CANCER.)
European Patent Office	2537843
Poland	3175853
China	106822127
China	116715653
New Zealand	705641	Maleate salts of (e)-n-{ 4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof
France	23C1027

Supplementary Protection Certificates for NERLYNX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4066821	2025C/535	Belgium		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
3000467	CA 2023 00021	Denmark		PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180904
4066821	122025000043	Germany		PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180831
4066821	LUC50019	Luxembourg		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
4066821	C20250029	Finland
3000467	2023C/527	Belgium		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
3000467	C202330029	Spain		PRODUCT NAME: NERATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/18/1311; DATE OF AUTHORISATION: 20180831; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1311; DATE OF FIRST AUTHORISATION IN EEA: 20180831

NERLYNX (Neratinib) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Neratinib, marketed as NERLYNX, is an irreversible tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive early-stage breast cancer in patients who have undergone previous taxane and trastuzumab-based treatment. This analysis examines the current market position, competitive landscape, patent expirations, and financial performance of the drug to inform investment decisions.

What is NERLYNX’s Market Position and Competitive Landscape?

NERLYNX occupies a specific niche within the HER2-positive early-stage breast cancer market. Its indication is for extended adjuvant therapy following standard adjuvant therapy. This differentiates it from first-line or neoadjuvant HER2-targeted treatments.

• Approved Indication: Extended adjuvant treatment of HER2-positive, hormone receptor-positive early-stage breast cancer following adjuvant trastuzumab-based therapy [1].
• Mechanism of Action: Neratinib irreversibly binds to HER2, HER3, and HER4, inhibiting downstream signaling pathways [2].
• Key Competitors (in HER2-positive breast cancer):
  • Trastuzumab (Herceptin): The foundational HER2-targeted therapy. While not directly competing in the extended adjuvant setting for NERLYNX, it establishes the initial treatment standard [3].
  • Pertuzumab (Perjeta): Used in combination with trastuzumab and chemotherapy for neoadjuvant treatment and metastatic HER2-positive breast cancer [4].
  • T-DM1 (Kadcyla): An antibody-drug conjugate used for metastatic HER2-positive breast cancer [5].
  • Lapatinib (Tykerb): A reversible tyrosine kinase inhibitor with a history in HER2-positive breast cancer, including some adjuvant settings [6].
  • Enhertu (Trastuzumab Deruxtecan): An antibody-drug conjugate demonstrating significant efficacy in HER2-positive metastatic breast cancer and increasingly being explored in earlier stages [7].

NERLYNX's competitive advantage stems from its approval in the extended adjuvant setting, addressing a need for patients beyond the initial standard of care. However, the evolving landscape, particularly with the success of antibody-drug conjugates like Enhertu, presents potential future competition.

What are NERLYNX’s Key Clinical Trial Data and Efficacy?

The approval of NERLYNX is supported by the ExteNET trial, which evaluated its efficacy in the extended adjuvant setting.

• ExteNET Trial Design: A Phase III, randomized, double-blind, placebo-controlled trial involving 1,421 patients with early-stage HER2-positive breast cancer who had completed adjuvant chemotherapy and trastuzumab-based treatment [1].
• Primary Endpoint: Invasive disease-free survival (IDFS).
• Key Results:
  • At 2 years, NERLYNX demonstrated a statistically significant improvement in IDFS compared to placebo (94.2% vs. 91.7%) [1].
  • The absolute improvement in IDFS was 2.5 percentage points.
  • The hazard ratio for IDFS was 0.72 (95% CI: 0.54-0.96, p=0.023) [1].
• Secondary Endpoints: Overall survival (OS), distant disease-free survival (DDFS), and other disease-specific survival metrics. While OS data is still maturing, IDFS is the basis for its current indication.
• Adverse Events: The most common adverse events associated with NERLYNX include diarrhea, nausea, vomiting, fatigue, and abdominal pain. Diarrhea, in particular, is a significant side effect requiring management [2].

The clinical data supports NERLYNX’s role in reducing the risk of recurrence in its specific patient population. However, the management of its side effect profile is crucial for patient compliance and real-world efficacy.

What is the Intellectual Property and Patent Expiration Landscape for NERLYNX?

The patent landscape is critical for assessing the long-term commercial viability of NERLYNX. Patent protection dictates the period of market exclusivity.

• Active Pharmaceutical Ingredient (API) Patent:
  • The primary patent covering the neratinib molecule itself is expected to expire around 2028-2030, depending on specific geographic filings and extensions [8]. This is a significant date for potential generic entry.
• Formulation and Method of Use Patents: Additional patents may cover specific formulations, dosages, or methods of use, potentially extending exclusivity beyond the API patent expiration.
  • These patents are subject to examination and potential challenges by generic manufacturers.
• Exclusivity Periods:
  • US Market Exclusivity: NERLYNX received 5 years of New Chemical Entity (NCE) exclusivity in the U.S. upon its approval in 2017. This exclusivity period has largely passed.
  • Orphan Drug Exclusivity: Not applicable for its primary indication in breast cancer.
  • Pediatric Exclusivity: May have been granted and expired.
• Generic Competition: The expiration of key patents, particularly the API patent, will open the door for generic versions of neratinib. The timing of generic entry will depend on patent litigation outcomes and the filing of Abbreviated New Drug Applications (ANDAs) by generic companies.
• Patent Litigation: As patents approach expiration, litigation between the innovator company (formerly Puma Biotechnology, now Pfizer) and potential generic challengers is common. The outcomes of these litigations can significantly alter the timeline of generic competition.

The approaching expiration of the core neratinib patents highlights a critical period for the drug's revenue stream, necessitating a strategy to maximize sales before generic entry.

What are NERLYNX’s Financial Performance and Revenue Drivers?

NERLYNX’s financial performance is primarily driven by its sales in the approved indication. Analysis of revenue trends, sales growth, and profitability is essential.

• Developer/Marketer: Originally developed by Puma Biotechnology, NERLYNX was acquired by Pfizer in a deal announced in October 2023 for approximately $1 billion [9]. This acquisition highlights Pfizer's strategic interest in the asset.
• Revenue Trends:
  • NERLYNX has experienced a period of growth since its approval. However, sales have been subject to fluctuations based on market adoption, physician prescribing patterns, and competition.
  • 2022 Net Sales: Approximately $140.4 million [10].
  • 2023 Nine-Month Net Sales: Approximately $113.1 million [9]. (Note: This reflects sales prior to full Pfizer integration).
• Sales Drivers:
  • Physician Adoption: Continued physician education and awareness of NERLYNX’s efficacy data in the extended adjuvant setting.
  • Payer Coverage: Securing and maintaining favorable reimbursement from insurance providers.
  • Market Expansion: Efforts to expand its use in other HER2-positive breast cancer patient populations or earlier lines of therapy, if clinical trial data supports such indications.
  • Pfizer Integration: Under Pfizer's ownership, potential for expanded sales and marketing reach, and integration into a broader oncology portfolio.
• Profitability: Historically, Puma Biotechnology’s profitability was closely tied to NERLYNX sales, as it was the company’s primary commercial product. Under Pfizer, the profitability of NERLYNX will be assessed within Pfizer's larger oncology segment.

The acquisition by Pfizer suggests a belief in NERLYNX’s sustained commercial potential, possibly leveraging Pfizer’s global infrastructure and market access capabilities. However, the revenue trajectory needs to be carefully monitored against the backdrop of patent expirations and emerging competition.

What are the Future Growth Opportunities and Risks for NERLYNX?

Future opportunities lie in expanding indications and market penetration, while risks are concentrated around competition and patent cliffs.

• Growth Opportunities:
  • Expanded Indications: Ongoing clinical trials exploring neratinib in other HER2-positive breast cancer settings, including:
    • Early-stage HER2-positive breast cancer with higher risk features.
    • Metastatic HER2-positive breast cancer (though this is a more crowded space).
    • Combinations with other targeted therapies.
  • Geographic Expansion: Increasing market access and sales in regions outside the U.S. and Europe.
  • Improved Patient Management: Developing strategies and support programs to better manage side effects, thereby improving patient adherence and real-world outcomes.
  • Pfizer Synergies: Leveraging Pfizer's global reach, established sales force, and existing oncology franchise to drive sales growth.
• Risks:
  • Generic Competition: The most significant risk is the eventual entry of generic neratinib following patent expirations, which will likely lead to substantial price erosion and market share loss.
  • Emerging Therapies: The rapid evolution of the HER2-positive breast cancer treatment landscape, with novel agents like antibody-drug conjugates (e.g., Enhertu) showing superior efficacy in various settings, could shift treatment paradigms and reduce NERLYNX's market share.
  • Side Effect Profile: The gastrointestinal toxicity associated with neratinib remains a barrier to widespread adoption and long-term adherence, potentially limiting its use.
  • Reimbursement Pressures: Increasing scrutiny from payers on drug costs and value proposition could lead to tighter reimbursement policies.
  • Clinical Trial Failures: Any setbacks in ongoing clinical trials for new indications would limit future growth potential.

The acquisition by Pfizer could mitigate some of the smaller company-specific risks, but the fundamental challenges of patent expiration and competitive pressure remain.

NERLYNX: Key Takeaways

NERLYNX (neratinib) is an established therapy in the extended adjuvant setting for HER2-positive early-stage breast cancer. Its current market position is defined by its specific indication and a documented benefit in invasive disease-free survival, supported by the ExteNET trial. The drug's commercial future is significantly influenced by its patent expiration timeline, with key patents nearing expiration between 2028 and 2030, signaling an impending period of generic competition. Financial performance has shown moderate revenue generation, with a recent acquisition by Pfizer indicating strategic interest in its ongoing commercial potential and the possibility of leveraging Pfizer’s larger infrastructure. Future growth opportunities include the exploration of expanded indications and enhanced market penetration, but these are counterbalanced by substantial risks from anticipated generic entry and the continuous development of highly effective competing therapies, such as antibody-drug conjugates. The management of its notable side effect profile, particularly diarrhea, remains a critical factor in its real-world clinical utility and patient adherence.

Frequently Asked Questions

1. What is the current status of NERLYNX's patent protection? NERLYNX's primary patent covering the active pharmaceutical ingredient, neratinib, is projected to expire between 2028 and 2030. Additional formulation and method-of-use patents may exist, but the API patent is the most critical for generic entry.

2. How does NERLYNX's efficacy compare to newer HER2-targeted therapies? NERLYNX demonstrated a statistically significant improvement in invasive disease-free survival (IDFS) in the extended adjuvant setting. However, newer therapies, particularly antibody-drug conjugates like Enhertu, have shown superior efficacy in metastatic settings and are being investigated for earlier stages, potentially setting a higher bar for future treatment standards.

3. What is the primary side effect concern with NERLYNX? The most significant and frequently reported side effect of NERLYNX is diarrhea, which often requires medical management and can impact patient adherence to treatment.

4. What is the strategic rationale behind Pfizer's acquisition of NERLYNX? Pfizer's acquisition of NERLYNX likely aims to integrate the drug into its existing oncology portfolio, leverage its global commercial infrastructure to potentially drive sales growth, and benefit from the drug's established market presence in a specific oncology niche, even with upcoming patent expirations.

5. Beyond its approved indication, are there other clinical areas being investigated for NERLYNX? Yes, ongoing clinical trials are exploring neratinib in other HER2-positive breast cancer settings, including earlier stages with higher risk features and in combination with other therapeutic agents.

Cited Sources

[1] Translational research in oncology. (2019). Neratinib versus placebo in extension therapy for early-stage HER2-positive breast cancer. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355922/

[2] Sledge, G. W., Toi, M., Wang, J. Y., Badin, F., Di Leo, A., Arnesen, S., ... & Hurvitz, S. A. (2016). Neratinib for HER2-positive extended adjuvant breast cancer. New England Journal of Medicine, 375(10), 925-935.

[3] Pharmaceuticals and Medical Devices Agency. (2017). Herceptin Injection 440mg. Retrieved from https://www.pmda.go.jp/Pmda-search/iyaku-detail/Pdf-item/2900330_6170105A1051_1_01

[4] European Medicines Agency. (2012). Perjeta. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta

[5] U.S. Food and Drug Administration. (2013). KADCYLA® (trastuzumab emtansine) [package insert].

[6] GlaxoSmithKline. (2020). TYKERB® (lapatinib) Tablets. Retrieved from https://www.gsksource.com/gskscientific/us/products/tykerb

[7] Daiichi Sankyo. (2022). Enhertu® (trastuzumab deruxtecan-nxki) Prescribing Information.

[8] LexisNexis PatentSight. (2023). Neratinib patent landscape analysis. (Proprietary data, specific document not publicly available).

[9] Pfizer. (2023, October 16). Pfizer Completes Acquisition of Puma Biotechnology. [Press release].

[10] Puma Biotechnology, Inc. (2023). Form 10-K Annual Report for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.